GSK plc — 13F Holdings & Portfolio
CIK 1131399 · latest 13F-HR filed 2026-05-14
GSK plc manages $599.2M in 13F-reported U.S. long-equity assets across 13 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are CRSP (25.57%), WVE (22.08%), BNTX (13.20%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 2, added to 3, and trimmed 7.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$599.2M
Long-equity book
13
Distinct positions
2026-03-31
Filed 2026-05-14
+0 / −2 / ↑3 / ↓7
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- VIR BIOTECHNOLOGY INC$25.1M +48.6%
- CVRX INC$2.4M +33.2%
- NKARTA INC$819.2K +14.1%
Top Trims
- WAVE LIFE SCIENCES LTD-$177.9M -57.4%
- LYELL IMMUNOPHARMA INC-$16.2M -34.8%
- CRISPR THERAPEUTICS AG-$15.7M -9.3%
- FULCRUM THERAPEUTICS INC-$6.5M -32.2%
- BIONTECH SE-$5.6M -6.6%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CRISPR THERAPEUTICS AG | CRSP | H17182108 | $153.2M | 25.57% | 3,220,627 | SH |
| 2 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $132.3M | 22.08% | 18,245,691 | SH |
| 3 | BIONTECH SE | BNTX | 09075V102 | $79.1M | 13.20% | 889,824 | SH |
| 4 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $76.6M | 12.79% | 8,550,954 | SH |
| 5 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $44.4M | 7.41% | 1,333,333 | SH |
| 6 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $30.3M | 5.06% | 1,512,659 | SH |
| 7 | CYTOKINETICS INC | CYTK | 23282W605 | $22.4M | 3.74% | 340,434 | SH |
| 8 | SPERO THERAPEUTICS INC | SPRO | 84833T103 | $21.5M | 3.59% | 9,190,606 | SH |
| 9 | FULCRUM THERAPEUTICS INC | FULC | 359616109 | $13.7M | 2.29% | 1,785,714 | SH |
| 10 | CVRX INC | CVRX | 126638105 | $9.5M | 1.59% | 1,007,583 | SH |
| 11 | BICYCLE THERAPEUTICS PLC | BCYC | 088786108 | $7.1M | 1.18% | 1,529,561 | SH |
| 12 | NKARTA INC | NKTX | 65487U108 | $6.6M | 1.11% | 3,150,732 | SH |
| 13 | REGENXBIO INC | RGNX | 75901B107 | $2.3M | 0.38% | 271,456 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $599.2M | 13 | 0001999371-26-010742 |
| 2025-12-31 | 2026-02-12 | $799.0M | 15 | 0001999371-26-003198 |